Amplifon (OTCMKTS:AMFPF) and bioMerieux (OTCMKTS:BMXMF) Head-To-Head Analysis

Amplifon (OTCMKTS:AMFPF) and bioMerieux (OTCMKTS:BMXMF) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk and institutional ownership.

Volatility & Risk

Amplifon has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, bioMerieux has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Amplifon and bioMerieux, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amplifon	0	2	2	0	2.50
bioMerieux	0	5	0	0	2.00

Valuation & Earnings

This table compares Amplifon and bioMerieux”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amplifon	$2.71 billion	0.97	$103.33 million	$0.36	33.36
bioMerieux	$4.60 billion	2.01	$449.73 million	N/A	N/A

bioMerieux has higher revenue and earnings than Amplifon.

Profitability

This table compares Amplifon and bioMerieux’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amplifon	2.87%	16.04%	4.20%
bioMerieux	N/A	N/A	N/A

Summary

Amplifon beats bioMerieux on 5 of the 9 factors compared between the two stocks.

About Amplifon

Amplifon S.p.A. engages in the distribution of hearing solutions and the fitting of customized products that help people rediscover various emotions of sound in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Ampli-easy, Ampli-connect, Ampli-energy, and Ampli-mini hearing devices. It also operates Ampli-care, a platform to deliver audiological care experience; and Amplifon App to manage the device functions in real-time directly from smartphone. Amplifon S.p.A. was founded in 1950 and is headquartered in Milan, Italy. Amplifon S.p.A.

About bioMerieux

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.